Delayed delivery of intravenous gentamicin in neonates: Impact of infusion variables

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 3, 2013, Pages 370-378

  Medlicott, Natalie J ^a   Reith, David M ^b   McCaffrey, Frances ^c   Krittaphol, Woravimol ^a   Broadbent, Roland S ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Neonatal Intensive Care Unit   (New Zealand)

Author keywords

drug delivery; gentamicin; intravenous infusion; neonatal

Indexed keywords

GENTAMICIN; GLUCOSE; SODIUM CHLORIDE;

ADSORPTION; ARTICLE; CONCENTRATION (PARAMETERS); DELAYED DRUG DELIVERY SYSTEM; DRUG DELIVERY SYSTEM; DRUG INFUSION; FILTER; HUMAN; INFUSION PUMP; LOW DRUG DOSE; NEWBORN; NEWBORN INTENSIVE CARE; SIMULATION;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; GENTAMICINS; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; SYRINGES;

EID: 84873082748     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12000     Document Type: Article

References (15)

1. Muller-Pebody B, et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed 2011; 96: F4-F8.
2. Hale LS, Durham CR,. A simple, weight-based, extended-interval gentamicin dosage protocol for neonates. Am J Health Syst Pharm 2005; 62: 1613-1616.
3. Rao SC, et al. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2011; (11): CD005091.
4. Martínková J, et al. Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life: an open-label, prospective study. Clin Ther 2010; 32: 2400-2414.
5. Begg EJ, et al. Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates. J Antimicrob Chemother 2009; 63: 1043-1049.
6. Lingvall M, et al. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 2005; 59: 54-61.
7. Sherwin CM, et al. Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. J Pharm Pharmacol 2009; 61: 465-471.
8. Nahata MC,. Intravenous infusion conditions. Implications for pharmacokinetic monitoring. Clin Pharmacokinet 1993; 24: 221-229.
9. Gould T, Roberts RJ,. Therapeutic problems arising from the use of the intravenous route for drug administration. J Pediatr 1979; 95: 465-471.
10. Giacoia GP,. Intravenous drug administration to low birthweight infants. Clin Pediatr 1987; 26: 25-29.
11. Lovich MA, et al. Central venous catheter infusions: a laboratory model shows large differences in drug delivery dynamics related to catheter dead volume. Crit Care Med 2007; 35: 2792-2798.
12. Jan DE, Raghaven S,. Adsorption of metanil yellow on a positively charged-modified nylon 66 membrane. Colloids Surf A Physicochem Eng Asp 1994; 92: 1-7.
13. Kishore BK, et al. Mechanism of protection afforded by polaspartic acid against gentamicin-induced phospholipidosis. I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phosphlipid bilayers in vitro. J Pharmacol Exp Ther 1990; 255: 867-874.
14. Simeon PS, et al. Continuous insulin infusions in neonates: pharmacological availability of insulin in intravenous solutions. J Pediatr 1994; 124: 818-820.
15. Zahid N, et al. Adsorption of insulin onto infusion sets used in adult intensive care unit and neonatal care settings. Diabetes Res Clin Pract 2008; 80: e11-e13.